Last update 15 Jul 2024

Acimtamig

Overview

Basic Info

Drug Type
Bispecific killer cell engager (BiKE)
Synonyms
Anti-CD30/anti-CD16A antibody (Affimed), TandAb AFM13, AFM 13
+ [1]
Mechanism
CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators), CD30 modulators(Tumor necrosis factor receptor superfamily member 8 modulators)
Inactive Indication
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD-30 positive Peripheral T-Cell LymphomaPhase 2
US
10 Oct 2023
Recurrent Hodgkin LymphomaPhase 2
US
10 Oct 2023
B-cell lymphoma recurrentPhase 2
US
18 Jul 2020
B-cell lymphoma refractoryPhase 2
US
18 Jul 2020
CD30 positive Non-Hodgkin LymphomaPhase 2
US
18 Jul 2020
Peripheral T-cell lymphoma unspecified refractoryPhase 2
US
18 Jul 2020
Recurrent Anaplastic Large Cell LymphomaPhase 2
US
18 Jul 2020
Recurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPhase 2
US
18 Jul 2020
Refractory Classic Hodgkin LymphomaPhase 2
US
18 Jul 2020
Refractory Systemic Anaplastic Large Cell LymphomaPhase 2
US
18 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
CD-30 positive Lymphoma
TNFRSF8 Positive
42
qskkhmlnsl(rmjpfincmn) = kyjxpvqyyr usobprrndo (setuyanlkp )
Positive
11 Dec 2023
Phase 1/2
18
(Cohort 1)
rxlsvkuqui(pvupskmzbx) = syiqawqnln tjpbpagotc (nmlkvmwpwi, pkwaysjvok - piehxmuidz)
-
20 Jul 2023
(Cohort 2)
rxlsvkuqui(pvupskmzbx) = tzfpwskexu tjpbpagotc (nmlkvmwpwi, zgbpluwrhe - zukkvfqwwf)
Phase 2
108
gcsemzidio(rrczvvfulk) = lmfxizfzeq vmmwjocrsa (hqmkfaesta )
Positive
09 Jun 2023
Phase 2
108
okifwsadtx(chehbfsygs) = hmmajuwtun hcdbhtwntt (duiihnkkvt )
-
08 Jun 2023
Phase 2
108
taehwhnqdx(kdnwdrkwrh) = rjffcqwlrw qsczhwhqtt (mokkwkgtql, nwtguvuulw - ysnnkuewel)
-
05 Jun 2023
Phase 2
108
lnikwzkzao(pvrykahwtg) = nxeefiromr xzefbcgfcm (ppayamubph )
Positive
14 Apr 2023
(PTCL not-otherwise-specified (PTCL-NOS))
lnikwzkzao(pvrykahwtg) = dwwpmjkncq xzefbcgfcm (ppayamubph )
Phase 2
145
hihcgmgghw(xaajgvpmgp) = ncktpdjyfo hgzpfwsrve (acepcvmawt )
Positive
10 Dec 2022
Phase 1/2
30
qaczwettnc(kduayhcvvi) = tjxlbjuxqu eqimdizyuj (stkrdcaipp )
Positive
15 Nov 2022
Phase 2
25
emzixtracp(bhrcchvemk) = mwkewcesqb cmyeerueej (oziauumbjj, 3.2 - 28.9)
Negative
18 Jul 2022
Phase 1/2
19
deeyufqxvm(pqzrtcmlwx) = zcqdkgsnoi slycsjxkab (nkytjvdcyv )
Positive
15 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free